Julian Center blames shortfall for counseling center closure
Shutting the 2-year-old counseling center’s doors in October will affect 179 patients, most of whom are victims of domestic violence or sexual assault.
Shutting the 2-year-old counseling center’s doors in October will affect 179 patients, most of whom are victims of domestic violence or sexual assault.
It looks like Eli Lilly and Co. has a winner. The Indianpaolis-based drugmaker’s experimental diabetes drug dulaglutide helped patients with Type 2 diabetes lose weight while suffering only manageable side effects, according to Phase 3 clinical trial data released over the weekend at the American Diabetes Association meeting in Chicago. According to Bloomberg News, dulaglutide, if approved, may be a significant competitor to Novo Nordisk A/S’ Victoza, which generated $1.64 billion in 2012. A clinical trial comparing the drugs may report results by the end of the year. “We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year. Dulaglutide is projected to sell $835 million in 2018, according to the average of six analysts’ estimates compiled by Bloomberg. Martin said the drug would be the only weekly injection in the class that doesn’t require patients to prepare the dose for administration.
The California Public Employees Retirement System saved $5.5 million, or 19 percent of its affected medical claims, under a two-year pilot project with Indianapolis-based WellPoint Inc. that steered patients away from high-cost health care providers that don’t produce better outcomes. WellPoint executives told Bloomberg News that the cost-capping, or reference-pricing, policy employed in the pilot program is now gaining momentum among employers. The California pension program, known as Calpers, became a partner in the pilot program after a WellPoint analysis found similar hip and knee surgeries cost anywhere from $15,000 to $110,000 per patient, with no difference in patient outcomes, according to Bloomberg. So in 2011, Calpers and WellPoint’s Anthem Blue Cross unit began steering patients toward 46 hospitals that agreed to keep their costs below $30,000—known as the program's “reference price.” If workers went to another provider, then they were responsible for any costs above $30,000. About 400 members opted for the designated hospitals in 2011, a 21-percent increase over previous years. Calpers’ in-patient costs for hip and knee surgeries dropped to an average of $28,695 from $35,400, according to WellPoint. The study was conducted by HealthCore, a research unit owned by WellPoint, and released Sunday at the AcademyHealth Annual Research Meeting in Baltimore.
Researchers at the Indiana University School of Medicine blocked the progression of Type 1 diabetes among newly diagnosed patients using a drug originally sold to treat psoriasis. In a clinical trial involving 49 patients, those who were given the drug alefacept (sold under the brand name Amevive) kept producing the same amount of insulin over the next year, while patients receiving a placebo saw their level of insulin drop over the same period. If the results are repeated in studies involving more patients, the drug could enable Type 1 diabetics to maintain some insulin production and avoid the debilitating complications caused by the disease, said Dr. Mark R. Rigby, a professor of pediatrics at the IU medical school. Nearly 3 million people are estimated to have Type 1 diabetes in the United States. Although the disease can be managed with insulin injections, it cannot be reversed or cured. Long-term complications can include visual impairment, heart disease, stroke, problems in the extremities leading to amputation, and other problems.
An Indiana University School of Medicine researcher has received a $3.8 million three-year grant from the National Institutes of Health to study estrogen as a treatment for schizophrenia using an unreleased drug developed by Eli Lilly and Co. A team led by Dr. Alan Breier, a professor of psychiatry at the IU medical school, will use a drug discovered by Lilly scientists that mimics some of the actions of the hormone estrogen, but without many of the side effects, such as feminization in men and uterine cancer in women. Breier's study is one of nine projects to receive support from a new NIH program called Discovering New Therapeutic Uses for Existing Molecules.
A study recently published in Archives of General Psychiatry has linked the growing incidence of autism to early-life exposure to pollution.
WINNER: Community Achievement in Health Care
Half of the candidates to replace retiring dean Dr. Craig Brater are from the IU medical school and the other half are outsiders, according to a release issued Monday by the Indiana University School of Medicine.
Dr. Thomas McAllister has been named chairman of the department of psychiatry at Indiana University School of Medicine. McAllister is currently vice chairman for neuroscience in the department of psychiatry at Dartmouth Medical School. McAllister received his undergraduate and medical degrees from Dartmouth.
Eskenazi Health appointed Dr. Mark Bustamante to manage primary care in Eskenazi’s community health centers throughout Indianapolis. Bustamante will serve as CEO of the newly designated Eskenazi Health Center federally qualified health center, formerly the division of primary care at Wishard Health Services. Wishard changed its name to Eskenazi Health this year.
Gary Everling has been named vice president of strategy and business development for Hendricks Regional Health in Danville. Everling holds a bachelor’s degree in business administration from Greenville College and an MBA from the University of Indianapolis. He has been in health care administration since 1998 and most recently served as system executive of business development for Indianapolis-based hospital system St. Vincent Health.
Fort Wayne-based Medical Informatics Engineering appointed Craig Mathison as vice president of finance. He most recently served as chief financial officer and president at Felderman Design-Build in Fort Wayne.
Dr. Zeba Madni, a psychiatrist, has joined Wishard Health Services. She received her medical degree in India and completed her residency in general psychiatry at Indiana University.
Dr. George Sheng, a vascular surgeon, has joined the CorVasc surgical practice, which is part of the St. Vincent Medical Group in Indianapolis. Sheng earned his bachelor’s degree in biology from Trinity University. He received his medical degree from Vanderbilt University School of Medicine in Nashville, Tenn.
Adam Horst, director the Office of Management and Budget under outgoing Gov. Mitch Daniels, will become vice president and controller at Indiana University Health. Horst will work under IU Health CFO Ryan Kitchell, who also was Horst’s boss for time in the Daniels administration. Horst holds a master’s degree in political science from Massachusetts Institute of Technology and a bachelor’s degree in government and psychology from Dartmouth College.
Under these definitions, some of our most-honored citizens could be considered mentally ill.
In a monthly feature that runs in the first issue of the month, through October, IBJ is identifying influential players in eight different industry categories. Formidable brainpower sums up the individuals included in our list of Who’s Who in Life Sciences.
Dr. Alexander B. Niculescu, a psychiatrist at the IU School of Medicine, has won a five-year, $1.5 million grant from the National Institutes of Health to hunt for the presence of certain proteins in the blood that would indicate that a patient suffers from a mood disorder, which afflicts one in five Americans.
Previous winners are not eligible for nomination, but previous finalists may be nominated. 2023 Health Care Heroes Community Achievement in Health Care CHOICE: Pregnancy and Substance Use Treatment Program – Top Honoree Burmese Outreach Team Hoosier Heartland Healing Collaborative Paws to Heal, a Paws to Think program Innovation in Health Care The Center for Physician […]
Dr. John Cummings has been named medical director of neurosurgery for Community Health Network. Cummings, a neurosurgeon at Community for more than 20 years, did his training at the Indiana University School of Medicine.
The IU Medical Group added two internists. Dr. Rebecca Lindberg earned her medical degree at Baylor College of Medicine in Houston and completed her residency at the IU School of Medicine. Dr. Laura Nelson did her medical training and residency at the IU medical school.
Forethought Financial Group Inc. named Ronald Ziegler chief actuary. He will oversee product development, financial reporting, and risk management at the Indianapolis-based life insurance company. Prior to joining Forethought, Ziegler spent 22 years at Transamerica/AEGON Insurance Group.
Dr. Jeffrey Kellams was installed as the 137th president of the Indianapolis Medical Society on Tuesday. He is a professor of clinical psychiatry at the IU School of Medicine, chief of psychiatric services at Wishard Health Services and medical director of the Midtown Mental Health Center in Indianapolis.
Dr. Tracy Price has joined Central Indiana Cancer Centers, providing radiation oncology services at its Fishers, Greenfield and Greenwood locations. Price did her medical training at the IU School of Medicine.
Dr. Eriko Onishi has joined St. Vincent Hospice to lead its effort to set up electronic medical records for physicians. Dr. Onishi, a native of Japan, is an internist specializing in terminal cancer. She previously served as a hospice medical director in Columbus, Ind.
Neurosciences center and administrative building would employ workers with annual salaries ranging from $27,000 for clerical staff to as high as $104,000 for management.
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Both of Lilly’s late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer’s. A drug that stops or reduces memory loss caused by Alzheimer’s may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
The Indiana Clinic, launched about a year ago, has signed 412 physicians as employees, and is still working
toward a goal of as many as 1,500 by 2011. The clinic, a joint venture of Clarian Health and the Indiana University
School of Medicine, is headed by Dr. John Fitzgerald. He discussed the progress.
By the year 2020, the United States is expected to face a nationwide shortage of at least 1 million nurses. Fishers-based
Orbis Education Services Inc. CEO Dan Briggs sees a potential profit center. Founded in 2003, IT startup Orbis aims to provide
the link between universities and hospitals for online delivery of nursing courses.
Eli Lilly and Co. became the first drug company to make public its grants to U.S. organizations by posting the records on its Web site today. Most of the grants focus on endocrinology, neurosciences, oncology and other areas where Lilly develops drugs. The largest in the first quarter was to Massachusetts General Hospital’s Department of […]
State officials are advancing plans to privatize a state-run hospital for the mentally ill and now are looking for a not-for-profit
to build and manage a new facility in Indianapolis.